Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Vu, Anh ^a   Sidhom, Maha S ^a   Bredbeck, Brooke C ^a   Kosmiski, Lisa A ^b   Aquilante, Christina L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adipokine; Metabolic syndrome; Omentin 1; Sexual dimorphism

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMENTIN 1; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OMENTIN 1 BLOOD LEVEL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84893368585     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-4     Document Type: Article

References (40)

1. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C, Biochim Biophys Acta 2005 1732 96 102 10.1016/j.bbaexp.2005.11.005 16386808 (Pubitemid 43267310)
2. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW, Am J Physiol Endocrinol Metab 2006 290 1253 1261 10.1152/ajpendo.00572.2004 16531507 (Pubitemid 43847911)
3. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Tan BK, Adya R, Randeva HS, Trends Cardiovasc Med 2010 20 143 148 10.1016/j.tcm.2010.12.002 21742269
4. Omentin plasma levels and gene expression are decreased in obesity. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC, Diabetes 2007 56 1655 1661 10.2337/db06-1506 17329619 (Pubitemid 46842600)
5. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. Auguet T, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, del Castillo D, Richart C, BMC Med Genet 2011 12 60 10.1186/1471-2350-12-60 21526992
6. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Pan HY, Guo L, Li Q, Diabetes Res Clin Pract 2010 88 29 33 10.1016/j.diabres.2010.01.013 20129687
7. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, Randeva HS, Diabetes 2008 57 801 808 10.2337/db07-0990 18174521
8. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC, Eur J Endocrinol 2011 165 789 796 10.1530/EJE-11-0375 21865408
9. Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS, Diabet Med 2008 25 1254 1255 10.1111/j.1464-5491.2008.02568.x 19046210
10. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Yan P, Liu D, Long M, Ren Y, Pang J, Li R, Exp Clin Endocrinol Diabetes 2011 119 257 263 10.1055/s-0030-1269912 21374544
11. Circulating omentin as a novel biomarker of endothelial dysfunction. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM, Obesity (Silver Spring) 2011 19 1552 1559 10.1038/oby.2010.351 21293447
12. Circulating omentin is associated with coronary artery disease in men. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T, Atherosclerosis 2011 219 811 814 10.1016/j.atherosclerosis.2011.08.017 21925659
13. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Liu R, Wang X, Bu P, Diabetes Res Clin Pract 2011 93 21 25 10.1016/j.diabres.2011.03.001 21497934
14. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Shang FJ, Wang JP, Liu XT, Zheng QS, Xue YS, Wang B, Zhao LY, Biomarkers 2011 16 657 662 10.3109/1354750X.2011.622789 21988056
15. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH, Cardiovasc Diabetol 2011 10 103 10.1186/1475-2840-10-103 22108456
16. Association of serum omentin-1 levels with coronary artery disease. Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, Shang DY, Acta Pharmacol Sin 2011 32 873 878 10.1038/aps.2011.26 21602837
17. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA, J Clin Endocrinol Metab 2013 98 514 517 10.1210/jc.2012-3673 23303213
18. Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, Circulation 2005 112 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765 (Pubitemid 41532612)
19. The metabolic syndrome-a new worldwide definition. Alberti KG, Zimmet P, Shaw J, Lancet 2005 366 1059 1062 10.1016/S0140-6736(05)67402-8 16182882 (Pubitemid 41338752)
20. The metabolic syndrome. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH, Endocr Rev 2008 29 777 822 10.1210/er.2008-0024 18971485
21. Adipose tissue dysregulation in patients with metabolic syndrome. Bremer AA, Devaraj S, Afify A, Jialal I, J Clin Endocrinol Metab 2011 96 1782 1788 10.1210/jc.2011-1577 21865369
22. Adipose tissue dysfunction in nascent metabolic syndrome. Bremer AA, Jialal I, J Obes 2013 2013 393192 23653857
23. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. Jialal I, Devaraj S, Adams-Huet B, Chen X, Kaur H, J Clin Endocrinol Metab 2012 97 1844 1850 10.1210/jc.2012-2498 22872691
24. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 499 502 4337382
25. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, J Biomed Inform 2009 42 377 381 10.1016/j.jbi.2008.08.010 18929686
26. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, Mueller H, de Wiza DH, Floerke RR, Smiris K, Lamb HJ, de Roos A, Bax JJ, Romijn JA, Smit JW, Akhyari P, Lichtenberg A, Eckel J, Diamant M, Ouwens DM, PLoS One 2013 8 59697 10.1371/journal.pone.0059697 23555749
27. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Rashid S, Watanabe T, Sakaue T, Lewis GF, Clin Biochem 2003 36 421 429 10.1016/S0009-9120(03)00078-X 12951168 (Pubitemid 37083556)
28. Adiponectin and high-density lipoprotein: a metabolic association through thick and thin. Toth PP, Eur Heart J 2005 26 1579 1581 10.1093/eurheartj/ehi374 15961408 (Pubitemid 41389686)
29. Adiponectin: mechanistic insights and clinical implications. Turer AT, Scherer PE, Diabetologia 2012 55 2319 2326 10.1007/s00125-012-2598-x 22688349
30. Plasma adiponectin levels and risk of myocardial infarction in men. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB, JAMA 2004 291 1730 1737 10.1001/jama.291.14.1730 15082700 (Pubitemid 38489895)
31. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB, Atherosclerosis 2011 219 322 329 10.1016/j. atherosclerosis.2011.07.011 21813129
32. Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D, Am J Med Sci 2013 345 455 461 10.1097/MAJ.0b013e318262dbef 23123561
33. Omentin as a novel biomarker of metabolic risk factors. Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T, Diabetol Metab Syndr 2012 4 37 10.1186/1758-5996-4-37 22835063
34. Circulating omentin concentration increases after weight loss. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G, Fernandez-Real JM, Nutr Metab (Lond) 2010 7 27 10.1186/1743-7075-7-27 20380714
35. The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels. Akbarzadeh S, Nabipour I, Assadi M, Movahed A, Jafari SM, Motamed N, Nazem H, Haraghy M, Pourbehi A, Bargahi A, Hajian N, Cytokine 2012 58 295 299 10.1016/j.cyto.2012. 02.005 22398372
36. Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Luque-Ramirez M, Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Alpanes M, Escobar-Morreale HF, Hum Reprod 2013 28 1908 1918 10.1093/humrep/det097 23559188
37. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF, J Clin Endocrinol Metab 2013 98 388 396 10.1210/jc.2012-3414 23337724
38. Study of Omentin1 and other adipokines and hormones in PCOS patients. Mahde A, Shaker M, Al-Mashhadani Z, Oman Med J 2009 24 108 118 22334855
39. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS, Diabetes 2010 59 3023 3031 10.2337/db10-0124 20852028
40. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Herder C, Karakas M, Koenig W, Clin Pharmacol Ther 2011 90 52 66 10.1038/clpt.2011.93 21654741